SNCA Is a Functionally Low-Expressed Gene in Lung Adenocarcinoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Increasing evidence links synuclein alpha (SNCA) to neurological disorders like Parkinson's disease (PD).
• The specific role of SNCA in human cancers, particularly lung cancers, remains largely uncharacterized.
• Lung adenocarcinoma (ADC) is a major subtype of lung cancer with significant unmet therapeutic needs.

Purpose of the Study:

• To investigate the expression levels of SNCA in lung adenocarcinoma (ADC).
• To evaluate the correlation between SNCA expression and the clinical prognosis of ADC patients.
• To explore the potential role of SNCA in chemoresistance in ADC.

Main Methods:

• Comprehensive bioinformatics analyses using Oncomine, Human Protein Atlas (HPA), and Cancer Cell Line Encyclopedia (CCLE) databases.
• Analysis of clinical study data to correlate SNCA expression with patient survival outcomes.
• Examination of Gene Expression Omnibus (GEO) datasets to assess SNCA levels in cisplatin-resistant ADC cells.
• Experimental validation using small interfering RNA (siRNA) to modulate protein tyrosine kinase 7 (PTK7) and its effect on SNCA expression in ADC cell lines.

Main Results:

• Significantly reduced SNCA expression was observed in both ADC tissues and cancer cell lines compared to normal controls.
• Down-regulation of SNCA was statistically correlated with shorter overall survival and post-progression survival times in ADC patients.
• Low SNCA levels were identified in cisplatin-resistant ADC cells.
• siRNA-mediated knockdown of PTK7 led to elevated SNCA expression in H1299 and H2009 ADC cell lines.

Conclusions:

• Low SNCA expression is a specific characteristic of lung adenocarcinoma (ADC).
• SNCA down-regulation is associated with poor prognosis and chemoresistance in ADC.
• SNCA represents a potential therapeutic target for a subset of lung cancers, warranting further investigation into its biological role in ADC.